{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T19:25:26Z","timestamp":1770492326489,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.eururo.2022.02.028","type":"journal-article","created":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T19:08:47Z","timestamp":1648321727000},"page":"606-614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non\u2013muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Gu\u00e9rin Immunotherapy"],"prefix":"10.1016","volume":"81","author":[{"given":"Roman","family":"Mayr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph M.","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ademi","family":"Santiago-Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahadi","family":"Baig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramesh","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna Cody","family":"Carcione","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Stoehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Otto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Erben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Breyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2022.02.028_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2022.02.028_b0010","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non\u2013muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0022-5347(05)64044-X","article-title":"A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival","volume":"169","author":"Shahin","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0020","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0025","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.20.01665","article-title":"Radical cystectomy against intravesical BCG for high-risk high-grade nonmuscle invasive bladder cancer: results from the randomized controlled BRAVO-Feasibility study","volume":"39","author":"Catto","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.02.028_b0030","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: new insights and updated recommendations","volume":"74","author":"Klaassen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ucl.2019.09.006","article-title":"Genomic and therapeutic landscape of non-muscle-invasive bladder cancer","volume":"47","author":"Cooley","year":"2020","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.eururo.2022.02.028_b0045","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.eururo.2007.12.026","article-title":"Prediction of progression of non\u2013muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study","volume":"54","author":"Burger","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0050","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.eururo.2010.05.043","article-title":"Molecular grade (FGFR3\/MIB-1) and EORTC risk scores are predictive in primary non\u2013muscle-invasive bladder cancer","volume":"58","author":"van Rhijn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0055","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2005.05.1771","article-title":"Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas","volume":"24","author":"Hern\u00e1ndez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.02.028_b0060","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.eururo.2007.01.009","article-title":"FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours","volume":"52","author":"van Oers","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0065","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/sj.ejhg.5200883","article-title":"Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders","volume":"10","author":"van Rhijn","year":"2002","journal-title":"Eur J Human Genet"},{"key":"10.1016\/j.eururo.2022.02.028_b0070","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00345-007-0213-4","article-title":"Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target","volume":"25","author":"Knowles","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0075","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/jclinpath-2020-207115","article-title":"Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder","volume":"74","author":"Al-Obaidy","year":"2021","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.eururo.2022.02.028_b0080","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.juro.2015.06.093","article-title":"FGFR3 down-regulation is involved in bacillus Calmette-Guerin induced bladder tumor growth inhibition","volume":"195","author":"Langle","year":"2016","journal-title":"J Urol"},{"issue":"suppl 6","key":"10.1016\/j.eururo.2022.02.028_b0085","doi-asserted-by":"crossref","first-page":"TPS603","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS603","article-title":"A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after bacillus Calmette-Gu\u00e9rin (BCG) therapy","volume":"38","author":"Steinberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2022.02.028_b0090","unstructured":"Clinicaltrials.gov. A study of pemigatinib in non-muscle invasive bladder cancer patients with recurrent low- or intermediate-risk tumors; 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03914794."},{"key":"10.1016\/j.eururo.2022.02.028_b0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2018.08.027","article-title":"Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0100","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2022.02.028_b0105","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.eururo.2022.02.028_b0110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2022.02.028_b0115","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.clgc.2018.01.009","article-title":"High CDKN2A\/p16 and low FGFR3 expression predict progressive potential of stage pT1 urothelial bladder carcinoma","volume":"16","author":"Breyer","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2022.02.028_b0120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00428-017-2064-8","article-title":"In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival","volume":"470","author":"Breyer","year":"2017","journal-title":"Virchows Arch"},{"key":"10.1016\/j.eururo.2022.02.028_b0125","doi-asserted-by":"crossref","first-page":"7726","DOI":"10.3390\/ijms21207726","article-title":"Non-muscle-invasive bladder carcinoma with respect to basal versus luminal keratin expression","volume":"21","author":"Jung","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eururo.2022.02.028_b0130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00262-017-2093-9","article-title":"High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients","volume":"67","author":"Breyer","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2022.02.028_b0135","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nrurol.2016.165","article-title":"Bladder cancer: low adherence to guidelines in non-muscle-invasive disease","volume":"13","author":"van Rhijn","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0140","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.juro.2011.09.008","article-title":"The FGFR3 mutation is related to favorable pT1 bladder cancer","volume":"187","author":"van Rhijn Bas","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2022.02.028_b0145","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1158\/1078-0432.CCR-05-0122","article-title":"FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis","volume":"11","author":"Hern\u00e1ndez","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.02.028_b0150","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1158\/0008-5472.CAN-03-2421","article-title":"FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma","volume":"64","author":"van Rhijn","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2022.02.028_b0155","unstructured":"Fowler M. Updated standard practice for managing patients with non-muscle-invasive bladder cancer; 2021. https:\/\/www.cancernetwork.com\/view\/updated-standard-practice-for-managing-patients-with-non-muscle-invasive-bladder-cancer."},{"key":"10.1016\/j.eururo.2022.02.028_b0160","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/1078-0432.CCR-21-0205","article-title":"Identification of a novel inflamed tumor microenvironment signature as a predictive biomarker of Bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer","volume":"27","author":"Damrauer","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2022.02.028_b0165","unstructured":"Clinton T, Almassi N, Dason S, et al. Response of FGFR3 alterations in high-grade non-muscle invasive bladder cancer treated with intravesical bacillus Calmette-Guerin therapy. Presented at: 20th Annual Society of Urologic Oncology (SUO 2019) meeting; December 4\u20136, 2019. Washington, DC."}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822016700?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283822016700?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:11:33Z","timestamp":1759583493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283822016700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0302283822016700"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2022.02.028","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non\u2013muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Gu\u00e9rin Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2022.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}